Participation in phase 1 trials for patients with cancer

[...]the treatment-related death risk always remained below 1% in all periods and across all cancers, except pancreatic cancer. [...]the sample size of CTEP-sponsored phase 1 studies was usually lower than those of industry-sponsored studies, increasing the risk of bias due to sparse data. Because s...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 400; no. 10351; pp. 473 - 475
Main Author:	Italiano, Antoine
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 13.08.2022 Elsevier Limited
Subjects:	Cancer Cancer therapies Clinical trials Clinical Trials, Phase I as Topic Cytotoxicity Drugs FDA approval Hematology Human subjects Humans Medical research Neoplasms - therapy Oncology Pancreatic cancer Participation Patient Participation Patients Pharmaceutical industry Response rates Tumors United States > US
ISSN:	0140-6736, 1474-547X, 1474-547X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!